Core Insights - Protagenic Therapeutics, Inc. has successfully closed a settlement and separation related to its previous acquisition of Phytanix Bio, which simplifies its capital structure and enhances operational focus on its lead product PT00114 [1] Financial Impact - The company has removed over $6.3 million in liabilities, contributing to a leaner financial position [1] - Annualized cost savings exceeding $1 million have been achieved, further strengthening the company's financial health [1] Strategic Focus - The transaction allows Protagenic to concentrate its efforts on developing PT00114, a first-in-class treatment for stress-related neuropsychiatric disorders, indicating a strategic pivot towards its core competencies [1]

Core Insights - Protagenic Therapeutics Inc. has reported positive topline safety results from its Phase 1 Multiple Dose study of PT00114, a synthetic analogue aimed at addressing stress-related neuropsychiatric conditions [1] Company Summary - Protagenic Therapeutics Inc. is focused on developing therapeutics that target the biology of chronic stress and its psychiatric and neurologic effects [1] - PT00114 is designed to restore homeostasis following prolonged exposure to stress, indicating its potential as a first-in-class treatment [1] Industry Context - The advancement into Phase 2 of PT00114 suggests a growing interest in addressing neuropsychiatric conditions linked to chronic stress, highlighting a potential market opportunity for innovative therapies in this area [1]

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling approximately 50 points, down 0.62% to 44,660.91, NASDAQ down 0.74% to 21,016.48, and S&P 500 down 0.66% to 6,353.29 [1] - Health care shares increased by 0.7%, while consumer staples stocks decreased by 0.9% [1] Company Performance - Walmart Inc. shares fell 4% after reporting mixed second-quarter results, with adjusted earnings per share of 68 cents, missing the analyst consensus estimate of 74 cents, but quarterly sales of $177.40 billion, up 4.8% year over year, exceeded expectations [2] Commodity Market - Oil prices decreased by 0.2% to $63.06, while gold also fell by 0.2% to $3,383.50; silver rose by 0.9% to $38.100, and copper fell by 0.2% to $4.4335 [5] European Market - European shares showed mixed results, with the eurozone's STOXX 600 down 0.07%, Spain's IBEX 35 down 0.10%, London's FTSE 100 up 0.18%, Germany's DAX 40 up 0.01%, and France's CAC 40 down 0.53% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 down 0.65%, Hong Kong's Hang Seng down 0.24%, China's Shanghai Composite up 0.13%, and India's BSE Sensex up 0.17% [7] Notable Stock Movements - Aptorum Group Limited shares surged 155% to $3.24 after receiving approval for the DiamiR APOE genotyping test [8] - Protagenic Therapeutics, Inc. shares increased by 94% to $4.43 after completing the first dose injections in its Phase 1 study [8] - SelectQuote, Inc. shares rose 40% to $2.5709 following better-than-expected fourth-quarter results and positive FY26 revenue guidance [8] - ModivCare Inc. shares dropped 61% to $0.7196 after filing for voluntary Chapter 11 [8] - Coty Inc. shares fell 20% to $3.8850 after missing fourth-quarter adjusted EPS, with Evercore ISI Group cutting its price target from $10 to $7 [8] - Canadian Solar Inc. shares decreased by 19% to $10.38 after reporting worse-than-expected second-quarter results and lowering FY25 sales guidance [8]